XJPX
4888
Market cap87mUSD
Oct 09, Last price
394.00JPY
1D
2.60%
1Q
21.60%
IPO
-45.35%
Name
Stella Pharma Corp
Chart & performance
P/E
—
P/S
43.88
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.33%
Rev. gr., 5y
9.44%
Revenues
323m
-66.35%
Net income
-781m
L+454.59%
CFO
-335m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.
Key people
Koki Uehara
President, Chief Operating Officer, Representative Director · since 2020
Hirotaka Ogawa
Executive Officer, Director of General Affairs
Kenji Ozaki
Executive Officer, Chief Director of Reliability Guarantee · since 2025
Toshimitsu Hayashi
Director of Pharmaceutical Affairs, Director of Clinical Development, Director · since 2022
Takahiro Kido
Director of Business Planning, Director · since 2022
Kazumitsu Yabu
Director · since 2020
Yoshiyuki Fukuchi
Independent Director · since 2024
Masaya Onishi
Independent Director · since 2018
Kohei Tsujii
Independent Director · since 2018
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||